Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 9, Issue 5, 2007, Pages 429-437

  Tajiri, Yuji ^a   Takei, Ryoko ^a   Mimura, Kazuo ^a   Umeda, Fumio ^a  

^a Fukuoka Medical Association Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NATEGLINIDE; PIOGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEX CHARACTERISTICS; THIAZOLIDINEDIONES;

EID: 35348829384     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0204     Document Type: Article

References (33)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996;45:1661-1669.
2. Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia 1999;42:1033-1049.
3. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185.
4. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46:433-439.
5. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-156.
6. Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T: Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998;41:121-129.
7. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
8. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
9. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
10. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-1820.
11. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
12. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Hans-Ulrich Haring HU, Koenig W, Marx N: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005;25:1804-1809.
13. Gaillard V, Casellas D, Seguin-Devaux C, Schohn H, Dauca M, Atkinson J, Lartaud I: Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 2005;46:372-379.
14. Plutzky J: Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001;12:511-518.
15. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B: The role of PPARs in atherosclerosis. Trends Mol Med 2002;8:422-430.
16. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T; Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55:65-85.
17. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
18. Gui Y, Silha JV, Murphy LJ: Sexual dimorphism and regulation of resistin, adiponectin, and leptin expression in the mouse. Obes Res 2004;12:1481-1491.
19. Orel M, Lichnovska R, Gwozdziewiczova S, Zlamalova N, Klementa I, Merkunova A, Hrebicek J: Gender differences in tumor necrosis factorα and leptin secretion from subcutaneous and visceral fat tissue. Physiol Res 2004;53:501-505.
20. Zoico E, Di Francesco V, Mazzali G, Vettor R, Fantin F, Bissoli L, Guariento S, Bosello O, Zamboni M: Adipocytokines, fat distribution, and insulin resistance in elderly men and women. J Gerontol A Biol Sci Med Sci 2004;59:M935-M939.
21. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y; the PRACTICAL Study Group: Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: post-marketing surveillance study in Japan. Diabetes Res Clin Pract 2007;76:229-235.
22. The Examination Committee of Criteria for "Obesity Disease" in Japan; Japan Society for the Study of Obesity: New criteria for "obesity disease" in Japan. Circ J 2002;66:987-992.
23. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1995;374:425-432.
24. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
25. Maruyama S, Yanagisawa K, Kanamuro R, Teno S, Iwamoto Y: Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;53:161-164.
26. Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S: Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997;46:342-347.
27. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-2948.
28. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
29. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289.
30. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737.
31. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y: Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-374891.
32. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
33. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.